Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety; in a 26-week phase 2 trial in 706 adults with overweight or obesity, once-weekly doses reduced body weight by 6.0% to 10.8% against 3.0% on placebo, with more nausea.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
emerging
Claim: Once-weekly cagrilintide reduced body weight dose-dependently in a phase 2 trialstanding
resolved
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL
A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.